Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 8:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–45 of 21 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Pancreatic Cancer
Interventions
Oxaliplatin, Irinotecan, Leucovorin, 5FU, Stereotactic Body Radiotherapy (SBRT)
Drug · Radiation
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 4 more
Conditions
Metastatic Pancreatic Adenocarcinoma
Interventions
BBI608, Nab-paclitaxel, Gemcitabine, Oxaliplatin, Leucovorin, Irinotecan, Fluorouracil, MM-398
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
12
States / cities
Phoenix, Arizona • Atlanta, Georgia • Fort Wayne, Indiana + 9 more
Conditions
Gastro-enteropancreatic Neuroendocrine Tumor, Pancreatic Cancer, Neuroendocrine Carcinomas of Pancreas, Islet Cell Carcinoma
Interventions
FOLFIRINOX, Granulocyte colony-stimulating factor (G-CSF)
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Pancreatic Cancer
Interventions
Atezolizumab, RO7198457, mFOLFIRINOX
Drug · Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Conditions
Stage III Pancreatic Cancer
Interventions
Modified FOLFIRINOX Regimen, NanoKnife System
Drug · Device
Lead sponsor
Angiodynamics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
Miami, Florida • Tampa, Florida • Arlington Heights, Illinois + 3 more
Conditions
Metastatic Pancreatic Cancer, Pancreatic Cancer
Interventions
Folfirinox
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Pancreatic Adenocarcinoma, Stage 0 Pancreatic Cancer American Joint Committee on Cancer v8, Stage I Pancreatic Cancer American Joint Committee on Cancer v8, Stage III Pancreatic Cancer American Joint Committee on Cancer v8, Stage IV Pancreatic Cancer American Joint Committee on Cancer v8
Interventions
Capecitabine, Fluorouracil, Irinotecan Hydrochloride, Leucovorin Calcium, Losartan Potassium, Oxaliplatin, Radiation Therapy, Resection, Diagnostic Imaging, Biospecimen Collection, Gemcitabine, Nab paclitaxel
Drug · Radiation · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Pancreatic Cancer
Interventions
mFOLFIRINOX, Stereotactic body radiotherapy (SBRT)
Drug · Radiation
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Pancreas Cancer
Interventions
anakinra, Oxaliplatin, Irinotecan, fluorouracil
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Stage I Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer
Interventions
oxaliplatin, leucovorin calcium, irinotecan hydrochloride, fluorouracil, therapeutic conventional surgery, laboratory biomarker analysis
Drug · Procedure · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
9
States / cities
Fairfield, Connecticut • Guilford, Connecticut • Hartford, Connecticut + 6 more
Conditions
Cancer of Pancreas, Cancer of the Pancreas, Neoplasms, Pancreatic, Pancreas Cancer, Pancreas Neoplasms
Interventions
Modified FOLFIRINOX, Stereotactic Body Radiotherapy (SBRT)
Drug · Radiation
Lead sponsor
Emory University
Other
Eligibility
21 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Atlanta, Georgia
Conditions
Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Advanced Pancreatic Cancer
Interventions
Folfirinox, Gemcitabine/nab-paclitaxel
Drug
Lead sponsor
University Health Network, Toronto
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
4
States / cities
Baltimore, Maryland • Boston, Massachusetts • New Hyde Park, New York + 1 more
Conditions
Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Fluorouracil, Irinotecan, Leucovorin Calcium, Magnetic Resonance Imaging, Oxaliplatin, Pegcetacoplan
Procedure · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Buffalo, New York
Conditions
Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer
Interventions
siG12D-LODER, Gemcitabine+nab-Paclitaxel, Folfirinox
Drug
Lead sponsor
Silenseed Ltd
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
4
States / cities
Hackensack, New Jersey • New York, New York • Houston, Texas
Conditions
Pancreatic Cancer
Interventions
CPI 613, Oxaliplatin, Irinotecan, 5-flurouracil, Folinic acid
Drug
Lead sponsor
David Bajor, MD
Other
Eligibility
18 Years to 80 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Pancreatic Adenocarcinoma
Interventions
Retifanlimab, Chemotherapy, 9-ING-41
Drug
Lead sponsor
Anwaar Saeed
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Pancreatic Cancer
Interventions
MVT-5873, modified FOLFIRINOX (mFOLFIRINOX), gemcitabine + nab-paclitaxel
Drug
Lead sponsor
BioNTech Research & Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
5
States / cities
Scottsdale, Arizona • Los Angeles, California • Sarasota, Florida + 2 more
Conditions
Pancreatic Cancer, Colorectal Cancer, Hepatocellular Carcinoma
Interventions
GLP1-RA (semaglutide)
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Tucson, Arizona
Conditions
Pancreatic Cancer Metastatic
Interventions
CPI 613, mFolfirinox, Folfirinox
Drug
Lead sponsor
Cornerstone Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
40
States / cities
Gilbert, Arizona • Tucson, Arizona • Duarte, California + 35 more
Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
Pembrolizumab, Folfirinox
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Houston, Texas
Conditions
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer
Interventions
6,8-bis(benzylthio)octanoic acid, oxaliplatin, leucovorin calcium, irinotecan hydrochloride, fluorouracil, laboratory biomarker analysis
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
1
States / cities
Winston-Salem, North Carolina